FDA consulted a Morquio A patient and several caregivers as it struggled to determine the clinical relevance of Vimizim’s effect on the six-minute walk test, apparently unbeknownst to the product’s sponsor, BioMarin Pharmaceutical Inc.
The consultation during FDA’s active BLA review process shows that patient groups can engage with FDA outside the context of an advisory committee, and reinforces
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?